For help on how to get the results you want, see our search tips.
375 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Categories
Human Remove Human filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Conditional approval Remove Conditional approval filter
Accelerated assessment Remove Accelerated assessment filter
Exceptional circumstances Remove Exceptional circumstances filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Verzenios (updated)
abemaciclib, Breast Neoplasms
Date of authorisation: 26/09/2018,
, Revision: 8, Authorised, Last updated: 21/04/2022
-
List item
Human medicine European public assessment report (EPAR): Nubeqa (updated)
darolutamide, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 27/03/2020,, Revision: 3, Authorised, Last updated: 20/04/2022
-
List item
Human medicine European public assessment report (EPAR): Rinvoq (updated)
upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019,, Revision: 8, Authorised, Last updated: 20/04/2022
-
List item
Human medicine European public assessment report (EPAR): Glyxambi
empagliflozin, linagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 11/11/2016,, Revision: 15, Authorised, Last updated: 13/04/2022
-
List item
Human medicine European public assessment report (EPAR): Regkirona
Regdanvimab, COVID-19 virus infection
Date of authorisation: 12/11/2021,, Revision: 2, Authorised, Last updated: 13/04/2022
-
List item
Human medicine European public assessment report (EPAR): Oxbryta
Voxelotor, Anemia; Anemia, Hemolytic; Anemia, Sickle Cell
Date of authorisation: 14/02/2022,, 
, Revision: 1, Authorised, Last updated: 13/04/2022
-
List item
Human medicine European public assessment report (EPAR): Ngenla
somatrogon, Growth and Development
Date of authorisation: 14/02/2022,, , Revision: 2, Authorised, Last updated: 13/04/2022
-
List item
Human medicine European public assessment report (EPAR): Ervebo
recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein, Hemorrhagic Fever, Ebola
Date of authorisation: 11/11/2019,, Revision: 6, Authorised, Last updated: 13/04/2022
-
List item
Human medicine European public assessment report (EPAR): Delstrigo
doravirine, lamivudine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 22/11/2018,, Revision: 7, Authorised, Last updated: 12/04/2022
-
List item
Human medicine European public assessment report (EPAR): Pifeltro
doravirine, HIV Infections
Date of authorisation: 22/11/2018,, Revision: 5, Authorised, Last updated: 12/04/2022
-
List item
Human medicine European public assessment report (EPAR): Imvanex
modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, Smallpox Vaccine
Date of authorisation: 31/07/2013,, 
, Revision: 20, Authorised, Last updated: 12/04/2022
-
List item
Human medicine European public assessment report (EPAR): Blitzima
rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017,, 
, Revision: 14, Authorised, Last updated: 12/04/2022
-
List item
Human medicine European public assessment report (EPAR): Byooviz
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Myopia, Degenerative
Date of authorisation: 18/08/2021,, , Revision: 2, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Abevmy
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021,, , Revision: 3, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Rukobia
fostemsavir trometamol, HIV Infections
Date of authorisation: 04/02/2021,, Revision: 2, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Vosevi
Sofosbuvir, velpatasvir, voxilaprevi, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,, 
, Revision: 11, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Veltassa
patiromer sorbitex calcium, Hyperkalemia
Date of authorisation: 19/07/2017,, Revision: 4, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Minjuvi
Tafasitamab, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 26/08/2021,, , 
, Revision: 3, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Nilemdo
Bempedoic acid, Hypercholesterolemia; Dyslipidemias
Date of authorisation: 01/04/2020,, Revision: 6, Authorised, Last updated: 08/04/2022
-
List item
Human medicine European public assessment report (EPAR): Tagrisso
osimertinib mesilate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, Revision: 15, Authorised, Last updated: 07/04/2022
-
List item
Human medicine European public assessment report (EPAR): Insulin lispro Sanofi
insulin lispro, Diabetes Mellitus
Date of authorisation: 19/07/2017,, , Revision: 7, Authorised, Last updated: 07/04/2022
-
List item
Human medicine European public assessment report (EPAR): Quofenix
delafloxacin meglumine, Skin Diseases, Bacterial
Date of authorisation: 16/12/2019,, Revision: 4, Authorised, Last updated: 07/04/2022
-
List item
Human medicine European public assessment report (EPAR): Abecma
idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021,, , , Revision: 4, Authorised, Last updated: 07/04/2022
-
List item
Human medicine European public assessment report (EPAR): Obizur
susoctocog alfa, Hemophilia A
Date of authorisation: 11/11/2015,, , Revision: 9, Authorised, Last updated: 07/04/2022
-
List item
Human medicine European public assessment report (EPAR): Lorviqua
Lorlatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2019,, , Revision: 9, Authorised, Last updated: 07/04/2022